Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANO-RAD: AGuIX with WBRT for Brain Metastases
NCT02820454Phase 1Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Mar 2016
- Primary completion
- Feb 2019
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AGuIX in brain metastases, sponsored by CHU Grenoble Alpes. Primary endpoint: Maximum-tolerated dose at 18 months. Started Mar 2016; status: completed.
02
Drugs
AGuIX
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT02820454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02820454.